| Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma NP Kristensen, C Heeke, SA Tvingsholm, A Borch, A Draghi, ... The Journal of clinical investigation 132 (2), 2022 | 74 | 2022 |
| Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers SK Saini, AD Ørskov, AM Bjerregaard, A Unnikrishnan, ... Nature communications 11 (1), 5660, 2020 | 64 | 2020 |
| Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma JS Holm, SA Funt, A Borch, KK Munk, AM Bjerregaard, JL Reading, ... Nature Communications 13 (1), 1935, 2022 | 46 | 2022 |
| T cell epitope prediction and its application to immunotherapy AL Schaap-Johansen, M Vujović, A Borch, SR Hadrup, P Marcatili Frontiers in Immunology 12, 712488, 2021 | 44 | 2021 |
| Tumor-infiltrating T cells from clear cell renal cell carcinoma patients recognize neoepitopes derived from point and frameshift mutations UK Hansen, S Ramskov, AM Bjerregaard, A Borch, R Andersen, A Draghi, ... Frontiers in immunology 11, 373, 2020 | 31 | 2020 |
| Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome VAB de Lima, A Borch, M Hansen, A Draghi, I Spanggaard, K Rohrberg, ... Cytotherapy 22 (4), 204-213, 2020 | 10 | 2020 |
| Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy A Borch, AM Bjerregaard, V Araujo Barbosa de Lima, O Østrup, CW Yde, ... Frontiers in genetics 14, 1058605, 2023 | 2 | 2023 |
| Identification and characterization of neoantigen-reactive CD8+ T cells following checkpoint blockade therapy in a pan-cancer setting KH Moss Jr, UK Hansen Jr, VAB De Lima Jr, A Borch Jr, ES Marquez Jr, ... bioRxiv, 2024.03. 17.585416, 2024 | 1 | 2024 |
| HLA-C restricted neoepitopes contribute significantly to the immune recognition of cancer S Ramskov, KU Hansen, KS Saini, T Sturm, A Borch, AM Bjerregaard, ... European Journal of Immunology 49 (Suppl. 3 SI), 387-387, 2019 | 1 | 2019 |
| IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition A Borch, I Carri, B Reynisson, HMG Alvarez, KK Munk, A Montemurro, ... Frontiers in Immunology 15, 1360281, 2024 | | 2024 |
